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Abstract
The aim of this study was to test the effect of a small volume administration of p-hydroxyphenylpyruvate (pHPP) in a rat
model of profound hemorrhagic shock and to assess a possible metabolic mechanism of action of the compound. The
results obtained show that hemorrhaged rats treated with 2–4% of the estimated blood volume of pHPP survived
significantly longer (p,0.001) than rats treated with vehicle. In vitro analysis on cultured EA.hy 926 cells demonstrated that
pHPP improved cell growth rate and promoted cell survival under stressing conditions. Moreover, pHPP stimulated
mitochondria-related respiration under ATP-synthesizing conditions and exhibited antioxidant activity toward mitochon-
dria-generated reactive oxygen species. The compound effects reported in the in vitro and in vivo analyses were obtained
in the same millimolar concentration range. These data disclose pHPP as an efficient energetic substrates-supplier to the
mitochondrial respiratory chain as well as an antioxidant supporting the view that the compound warrants further
evaluation as a therapeutic agent.
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Introduction
Trauma death is a leading cause of death throughout the world
[1]. The most common cause of death in polytrauma patients is
hemorrhagic shock (HS). Hemorrhage leads to reduced tissue
perfusion and, if prolonged, irreversible cell damage caused by
depletion of substrate availability, [2,3]. Standard management for
HS consists of the intravenous administraton of adequate volumes
of sanguinous and asanguinous fluids [4]. However, administration
of large volumes of resuscitation fluids can be associated with
increased blood loss, exacerbation of acute lung injury and high
mortality [5,6]. Accordingly, investigators have been interested in
developing therapeutic approaches, which can prolong survival of
patients with HS without requiring the administration of a large
volume of resuscitation fluid.
Previous work showed that treatment with a resuscitation fluid
containing ethyl pyruvate (EP), a hydrolyzable ester of pyruvate,
can improve survival in rats or mice subjected to profound HS
[7,8]. However, results from a clinical trial failed to find any
evidence for therapeutic effect of EP in patients undergoing
cardiac surgery [9]. Nevertheless, many laboratories continue to
investigate the therapeutic potential of EP as well as other related
compounds [10–12]. Para-hydroxyphenylpyruvate (pHPP) is an
intermediary metabolite in the catabolic pathway of phenylalanine
and tyrosine (Fig. 1) chemically related to EP. In the present study,
we found that administration of a small volume of a solution of
pHPP can prolong the survival of rats subjected to profound HS.
In order to elucidate the mechanism for this protective effect, we
carried out additional in vitro studies, using cultured EA.hy 926,
human endothelial-like cells unveiling unexpected bio-energizing
properties of the compound.
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Materials and Methods
Cell Cultures
EA.hy 926 human endothelial-derived cells were obtained from
American Type Culture Collection (ATCC, Manassas, VA) and
maintained at 37uC in DMEM supplemented with 10% fetal
bovine serum (FBS) (Hyclone Laboratories, Logan, UT), 1%
penicillin/streptomycin, 1% pyruvate, and non-essential amino
acid supplement (1% v/v).
Materials
pHPP, homogentisate (HGA), dichloroacetate (DCA), 2-deox-
yglucose (2-DG), rotenone, oligomycin, and carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP) were from Sigma-
Aldrich Chemical Co. (St Louis, MO).
Study Design for Survival of Rats Subjected to Severe
Volume-controlled HS
The guidelines for the use of experimental animals of the U.S.
National Institutes of Health were followed and approved by the
Institutional Animal Care and Use Committee at the University of
Pittsburgh. Controlled HS was performed following a previously
reported protocol [7]. Briefly, male Sprague-Dawley rats (Charles
River Laboratories, Wilmington, MA) weighting 250 to 300 g
were anesthetized with intramuscular ketamine HCl at 30 mg/kg
and intraperitoneal sodium pentobarbital at 65 mg/kg. Lidocaine
(1%, Abbot Laboratories) was provided locally before performing
surgical cutdown sites. The right jugular vein was exposed, ligated
distally, and cannulated with polyethylene tubing (PE 10) to infuse
the test solution. PE 10 was inserted in the isolated and distally
ligated femoral artery and attached to a pressure transducer for
measurement of the mean arterial pressure (MAP). A silicon
catheter (Cronic Cath, Norfolk Medical, Skokie, IL) was intro-
Figure 1. Catabolic pathway of phe/tyr. The scheme illustrates the individual enzymatic steps and intermediates of the catabolism of phe/tyr to
acetoacetate and fumarate in the cytoplasmic compartment and their further metabolization within mitochondria. PAH, phenylalanine hydroxylase;
BH4, tetrahydrobiopterin; TAT, tyrosine aminotransferase; HPPD, 4-hydroxyphenylpyruvate dioxygenase; HGD, homogentisate dioxygenase; MAAI,
maleylacetoacetate isomerase; FAH, fumarylacetoacetate hydrolase; DCA, dichloroacetate; TC, tricaboxylic acid cycle; OXPHOS, oxidative
phosphorylation.
doi:10.1371/journal.pone.0090917.g001
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duced into the femoral vein and was used to withdraw blood.
Animals were placed in a supine position on a thermal blanket to
maintain their body temperature at 37uC. Following surgical
preparation and a 5-min stabilization period, rats were subjected
to HS. Bleeding was carried out in two phases: 21.7 ml/kg of
blood was withdrawn over 20 min, followed immediately by an
additional 14 ml/kg over 40 min. The total blood loss was
35.7 ml/kg or approximately 52% of the total estimated blood
volume (EBS) [13]. The animals were randomly assigned to one of
the following treatment groups (n = 6). Group 1 was administered
2.8 ml/kg of normal saline (<4% of EBV); Group 2 was
administered an equivalent volume of 0.25 mmol/kg pHPP
solution; Group 3 received the same 0.25 mmol/kg of pHPP in
50% less of the saline vehicle (i.e., 1.4 ml/kg or <2% of EBV);
Group 4 was given 0.25 mmol/kg of homogentisate (HGA) in
2.8 mL/kg of saline; Group 5 was administered 1 g of dichlor-
oacetate (DCA) in 2.8 mL/kg of saline; Group 6 received 1 g of
DCA per kg in 1.4 mL/kg of saline +0.25 mmol/kg of pHPP in
1.4 mL/kg of saline. The treatment was administered as a
continuous infusion during the last 20 min of the hemorrhage
period. Blood pressure was monitored continuously as in [7].
Blood-related parameters (i.e. pH, hemoglobin, base excess, pO2,
pCO2, SpO2, lactate, and glucose) were determined on 0.3 ml of
blood samples, collected through the arterial catheter, at the
beginning of hemorrhage (T0) and 30 min after the resuscitation
ended (T90) using a commercial blood gas analyzer. Rats were
observed until expiration (defined by apnea for .1 min) as direct
result of the intervention.
Impedance Measurements
Impedance-based real time detection of cellular viability was
conducted using the xCELLigence system Real-Time Cell
Analyzer RTCA-MP (Roche Diagnostics, Penzberg, Germany)
in designated 96 well E-plates (Roche, Penzberg, Germany).
Recording of cell index values (CI), background subtraction and
normalization was performed using the RTCA Software 1.2
(Roche Diagnostics, Penzberg, Germany). The impedance readout
as recorded by the xCELLigence system is expressed as arbitrary
cell index-values.
Respirometry
Oxygen consumption rates (OCR) in intact cells were measured
by high resolution oxymetry (Oxygraph-2K, Oroboros) in
thermostatically controlled tween-chambers (T= 37uC) equipped
with a stirring device and a gas-tight plug equipped with a narrow
port enabling addition of solutions by microsyringe. Cultured
EA.hy 926 cells were detached from the plate by trypsinization,
washed in PBS and suspended at 1–26106 cells/ml in 50 mM
KH2PO4, 10 mM Hepes, 1 mM EDTA, 10 mM glucose, pH 7.4
in both the oxymeter chambers. Respiration of untreated and
pHPP-treated cells were assayed in parallel. In the latter case, the
assay buffer was supplemented directly with pHPP to obtain the
desired final concentration. After achievement of the stationary
resting oxygen consumption rate (OCRR), 1.0 mg/mL of oligo-
mycin was added (OCRO) followed after 5 min by the addition of
75–150 nM of the uncoupler FCCP (OCRU); the measured OCRs
were corrected for the 2 mM rotenone-insensitive respiration.
Subcellular Fractionation
Bovine heart mitochondria were isolated by differential
centrifugation as described [14]. The supernatatant after the first
high-speed centrifugation was taken as the soluble cytoplasmic
fraction.
Laser Scanning Confocal Microscopy Live Cell Imaging of
Mitochondrial ROS
Cells cultured at low density on fibronectin-coated 35-mm glass-
bottom dishes were incubated for 15 min at 37uC with 0.5 mM
MitoSox (Molecular Probes, Eugene, OR) for detection of intra-
mitochondrial superoxide (O2
?2). Stained cells were examined
with a Nikon TE 2000 microscope (images collected using a 606
objective [1.4 NA]) coupled to a Radiance 2100 dual-laser LSCM
system (Bio-Rad); red fluorescence was elicited by exciting with the
He-Ne laser beam (lex 543 nm). Acquisition, storage, and analysis
of data were performed with LaserSharp and LaserPix software
from Bio-Rad or ImageJ version 1.37 (http://imagej.nih.gov/ij/).
Superimposed confocal planes were analyzed by the ‘‘stack’’
function of the LCS-Analysis Tools which produced a xz intensity
profile of the average value of the pixels within marked edges,
including a single cell, as a function of each focal plane. The
integrated value of the xz profile was taken as a measure of the
fluorescence intensity of that individual cell relative to the selected
emission channel. Correction was made for the minimal
background by repeating the procedure in a cell-free field. About
one hundred single cells were analyzed for each imaging analysis.
Statistics
Data are presented as means 6 SEM and analyzed using
analysis of variance (ANOVA) or two-tailed student t-tests, as
appropriate. Survival data were analyzed using Kaplan Meier
survival analysis and the log rank test. A value of P,0.05 was
considered statistically significant.
Results
Effect of pHPP on Survival of Rats Subjected to
Experimental HS
Rats (6 animals per group) were subjected to hemorrhage over a
total period of 60 min and the total blood lost was approximately
52% of the EBV (<18.9 ml/0.275 kg/rat) [13]. Twenty min
before the end of the HS, rats were infused with small volumes of
normal saline solution without or with added compounds. The
infused volumes were <4% or <2% of the EBV (i.e., the
hemorrhaged rats were ‘‘resuscitated’’ with only very small
volumes of asanguinous fluids). Figure 2A illustrates the Kaplan-
Meyer survival analysis of the experiment. It shows that all animals
survived at least 1 h following the initiation of hemorrhage. All
animals treated with saline in the control group died within
140 min. The rats treated with 0.25 mmol/kg of pHPP in 4% or
2% of EBV survived significantly longer (p,0.001). Five of 12
animals treated with pHPP survived longer than 4 h and 1 rat
survived for 455 min. The infused dose of pHPP resulted in an
estimated circulating concentration of about 7 mM.
pHPP, as intermediate of the phenylalanine/tyrosine (phe/tyr)
catabolism, is converted to HGA (Fig. 1). Treatment with HGA
(2% of EBV) resulted in 33.3% of rats surviving until 5 h. No
statistical difference was observed among rats treated with pHPP
solution (4% of estimated blood volume), pHPP solution (2% of
estimated blood volume), or HGA solution (2% of estimated blood
volume).
DCA is an inhibitor of the maleylacetoacetate-cis-trans isomerase
[15], an enzyme, which catalyzes the terminal step in the phe/tyr
catabolism pathway. Data shown in Fig. 2A indicate that all rats
infused with a millimolar concentrations of either DCA alone or
DCA+pHPP died within 4 h.
Rats subjected to HS were continuously monitored for
hemodynamic parameters. Before induction of hemorrhage, there
were no significant differences in hemodynamic variables and
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blood gases among groups (not shown). Figure 2B shows that
hemorrhage induced a significant decrease in the mean arterial
pressure (MAP) during the first 40 min when compared with
baseline values. Forty min after the beginning of treatment, at T80
of the experiment, MAP of all groups, except control, yielded a
slight increase to values not significantly different among the
groups. Thereafter, at T120, MAP was similar in rats treated with
pHPP or HGA. Rats treated with DCA or DCA+pHPP tended to
have the highest MAP levels (Fig. 2B). No significant changes in
arterial blood samples occurred among groups at T0 and T80.
Effect of pHPP on Cell Growth and Viability
To verify the impact of pHPP on the overall cell physiology, we
tested, in vitro, the impact of the compound on the growth rate of
the human endothelial-derived EA.hy 926 cells cultured on plates
suited for measuring electrical impedance. The impedance
measurement provides quantitative information about the biolog-
ical status of the cells, including cell number, viability, and
morphology [16]. Figure 3A shows that supplementation of 2.5–
10 mM pHPP to cultured cells in serum-complemented DMEM
significantly enhanced the cell index (CI) in the first 24 h.
However, in the following 48 h only 2.5 mM pHPP was able to
sustain enhanced cell growth.
Figure 2. Survival and hemodynamic analysis of rat subjected to severe volume-controlled HS. Rats were subjected to severe volume-
controlled HS as described in Materials and Methods. Twenty min before the end of the hemorrhage, rats were infused with either of the following
small-volume solutions: saline 2.8 ml/kg (4% of EBV; saline 4%); 0.25 mmol/kg of pHPP in 2.8 ml/kg of saline (4% EBV; pHPP 4%); 0.25 mmol/kg of
pHPP in 1.4 ml/kg of saline (2% EBV; pHPP 2%); 0.25 mmol/kg of HGA in 2% EBV of saline (HGA 2%); 1 g/kg of DCA in 4% EBV of saline (DCA 4%); 1 g/
kg of DCA in 2% EBV of saline +0.25 mmol/kg of pHPP in 2% EBV of saline (DCA 2%+pHPP 2%). Panel A shows Kaplan-Meier survival curves. * and #,
P,0.05; **, P,0.001. Panel B shows mean arterial pressure of rats subjected to HS.
doi:10.1371/journal.pone.0090917.g002
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To assess whether pHPP was an efficient bio-energizer even
under conditions associated with cell stress, we tested the effect of
the compound on the viability of cells subjected to an abrupt
change in the culture medium. As shown in Fig. 3B, substitution of
complete DMEM medium with a saline buffer resulted in a
dramatic fall of the CI within 30 min. When the saline buffer was
supplemented with 10 mM pHPP the decrease of the CI was
largely prevented. However, lower concentrations of pHPP (i.e.
2.5 and 5 mM) were, under this condition, inefficient.
Figure 3C shows that when EA.hy 926 cells were precondi-
tioned to promote deficiency of respiratory substrates and serum
factors the pro-survival effect of 10 mM pHPP was even stronger
when cells were suddenly challenged with the saline buffer. Under
this setting, the protective effect of pHPP was completely
prevented by DCA.
Effect of pHPP on Respiratory Activity
As intermediate in the phe/tyr catabolic pathway pHPP leads to
the formation of acetoacetate and fumarate; these compounds are
mitochondrial respiratory substrates (Fig. 1). In order to determine
whether pHPP is a suitable precursor of respiratory substrates, we
tested the effect of pHPP on the respiration of intact EA.hy 926
cells by high resolution oxymetry. Figure 4A shows basal oxygen
consumption rates (OCRR) of the cells in media supplemented
with different concentrations of pHPP. A clear biphasic effect of
pHPP is evident. Whereas 2.5 mM pHPP resulted in significant
stimulation of oxygen consumption (<90% increase as compared
with untreated cells, P,0.001), higher concentrations of pHPP
were associated with an attenuation of the stimulatory effect.
When respiratory activity was assayed in the presence of the FoF1-
ATP synthase inhibitor, oligomycin, the oxygen consumption rate
Figure 3. Effect of pHPP on cell growth and cell viability under stressing conditions. EA.hy 926 cells (104 in 100 ml of complete DMEM +
10% FBS) were left to adhere to the bottom of the impedentiometric microplate wells in a controlled environment. Impedance was recorded
continuously every 5 min and expressed as cell index (CI). (A) Once the CI reached a steady value, the medium was substituted with DMEM
containing dissolved pHPP at the indicated concentrations and the impedance recorded for three days. The time scale has been split to distinguish
early from late phases and the CI scale enlarged in the left part of the diagram. The values shown are means of 2 independent experiments. (B) Cells
were incubated in complete DMEM for 5 h and then the medium substituted with PBS without or with the indicated concentrations of pHPP and the
CI recorded for the following 5 h. The values shown are means of 2 independent experiments. (C) Cells were incubated with serum- and glucose-free
DMEM (DMEM -S, -G) without or with 10 mM pHPP620 mM DCA and CI recorded for the following 23 h. Subsequently, the medium was changed to
PBS supplemented without or with the same compounds as before. The traces were normalized to the CI values reached before the medium change;
each time point is the average 6 SEM of 3 independent experiments. The right panel depicts representative phase contrast micrographs of the cells
at the end of the experiment; the dark connected circles are the micro-electrodes at the bottom of the impedentiometric wells.
doi:10.1371/journal.pone.0090917.g003
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Figure 4. Respirometric analysis of EA.hy 926 cells. Intact EA.hy 926 cells were assayed by high-resolution respirometry in the buffer described
in Materials and Methods supplemented with the indicated concentrations of pHPP. Panel A depicts OCR measured under resting phosphorylating
conditions (OCRR), in the presence of FoF1-ATP synthase inhibitor oligomycin (OCRO), or in the presence of the protonophoric uncoupler FCCP
(OCRU). The bar-values were corrected for the residual OCR measured in the presence of the respiratory chain blocker rotenone (shown in the inset)
and are means 6 SEM of 4–6 independent experiments under each condition. Panel B shows OCR linked to ATP synthesis obtained from the values
shown in (A) subtracting OCRO from the OCRR. Panel C shows the respiratory control ratios (RCR) obtained from the values shown in (A) dividing
OCRU by the OCRO. *, P,0.05; **, P,0.01 (vs untreated). (D) OCRU was measured as described in (A); the inhibitors of the tyrosine catabolism and of
glycolysis (DCA and 2-DG, respectively) were tested at the indicated concentrations on the respiratory activity assessed in the absence or in the
presence of 2.5 mM pHPP. The bar values are percentages of the OCRU measured in control untreated cells and are the means 6 SEM of 4–5
independent experiments under each condition. *, P,0.05, **, P,0.01 (vs inhibitor-untreated).
doi:10.1371/journal.pone.0090917.g004
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(OCRO) did not change significantly in the tested pHPP
concentration range.
Addition of the protonophore FCCP, which uncouples the
oxidation of substrates from the phosphorylation of adenosine
diphosphate (ADP) recovered the respiratory activity (OCRU) to
that attained under resting condition and recapitulated a similar
dose-response effect of pHPP.
The effect of pHPP on OCR was sensitive to rotenone (or
KCN, not shown) and therefore attributable to mitochondrial
respiratory chain-dependent respiration. Noticeably, the rotenone-
insensitive OCR (i.e., the rate of oxygen consumption that is
independent of the mitochondrial respiratory chain) increased
significantly in the presence of pHPP (inset of Fig. 4A) leveling off
at a 10% of the rotenone-sensitive OCRR measured in the
presence of 5 mM pHPP. The phosphorylation-dependent OCR
(i.e. OCRR-OCRO) as well as the respiratory control ratio (i.e.
OCRU/OCRO) displayed a clear and upside-down U-shaped
dependence on pHPP concentration (Figs. 4B and 4C).
In order to investigate whether the observed pHPP-mediated
increase of respiratory activity was linked to catabolism of the
compound, we evaluated the effect of DCA. Figure 4D shows that
10 mM DCA abrogated completely the stimulatory effect on the
OCRU attained at 2.5 mM pHPP whereas it caused only a modest
decrease of respiratory activity in untreated cells. Conversely,
treatment of cells with 2-deoxyglucose (2-DG), an inhibitor of the
glycolytic pathway, resulted in a relatively much larger depression
of the OCRU in control as compared with the pHPP-treated cells.
Finally, since the catabolism of pHPP is expected to occur
initially in the cytoplasmic compartment of the cell and then to
continue in mitochondria, we examined the effect of pHPP on
OCR in subcellular fractions obtained from homogenized
bovine heart. Figure 5 shows that the addition of isolated
mitochondria to either a medium containing 2.5 mM pHPP or
to the soluble cytoplasmic fraction, but without pHPP, did not
result in any oxygen consumption. Conversely, when mitochon-
dria were added to the cytoplasmic fraction supplemented with
pHPP, a rapid oxygen consumption was observed, which was
almost completely inhibited by the mitochondrial respiratory
chain inhibitor rotenone and substantially inhibited by 10 mM
DCA. We observed a small, but nonetheless detectable OCR,
when the cytoplasmic fraction was incubated with pHPP before
the addition of isolated mitochondria. This last observation and
the mitochondrial-independent oxygen consumption effect
shown in Fig. 4A are consistent with the notion that the
cytoplasmic conversion of pHPP to acetoacetate and fumarate
requires two enzymatic steps catalyzed by O2-consuming
oxygenases (see Fig. 1).
Effect of pHPP on Mitochondrial Reactive Oxygen Species
Production
Enone containing compounds like EP and pyruvate were
shown to function as scavengers of reactive oxygen species
(ROS) [17,19]. To test this property for pHPP, its effect on
ROS production by endothelial cells was assessed by confocal
microscopy imaging of cells treated with the fluorescent probe
MitoSox, which accumulates into mitochondria and reacts
preferentially with the superoxide anion (O2
?2) therein [20].
Figure 6 shows a representative image of EA.hy 926 cells
cultured under normal growth conditions (i.e. DMEM +10%
FBS) stained with MitoSox. Basal production of ROS can be
appreciated by the probe-related intracellular red fluorescence.
To note, the brightest fluorescent signal was punctuate as
expected for the mitochondria-targetted probe. Treatment of
cells in tween samples with pHPP (10 mM for 45 min) resulted
in a clear and significant decrease of the ROS-related
fluorescent signal. To further challenge the antioxidant activity
of pHPP under pro-oxidative stressing conditions, endothelial
cells were growth for 4 hours in the absence of FBS. As shown
in Fig. 6 this condition resulted in a significant almost three-fold
increase of ROS production (consistent with previous reports
Figure 5. Effect of subcellular fractions on pHPP-dependent respiratory activity. (A) Representative respirometric traces. Isolated beef
heart mitochondria were added, where indicated, at the concentration of 0.5 mg prot/ml in either of: (trace a) the cytoplasmic fraction isolated from
bovine heart homogenate; (trace b) 0.25 M sucrose, 0.1 mM EDTA, 10 mM Tris-HCl pH 7.8 containing 2.5 mM of dissolved pHPP; (traces c) the
cytoplasmic subcellular fraction containing 2.5 mM of pHPP. Where indicated, 2 mM rotenone or 10 mM DCA were added. (B) The histogram shows
the mitochondrial OCR (means 6 SEM) of three independent experiments under each condition, measured in the absence (a) or in the presence (b
and c) of pHPP; the values shown were corrected for the rotenone (-rot.)- or the DCA (-DCA)-insensitive OCR. * and ** indicate P,0.05 and P,0.001 vs
the other conditions; #, P,0.01 ((c)-Rot. vs (c)-DCA).
doi:10.1371/journal.pone.0090917.g005
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[21]), which was largely prevented by pHPP and kept within
the basal levels.
Collectively these data suggest that pHPP exerts a cellular
protective effect not only providing substrate for fuel but also via
Figure 6. Confocal microscopy analysis of the effect of pHPP on production of mitochondrial superoxide anion in cultured cells.
EA.hy 926 cells were grown on coverslips in complete DMEM +10% FBS (A) or without FBS (B) (for 4 hours) either in the absence and in the presence
of 10 mM pHPP followed by addition of the mt-O2
.2 fluorescent probe MitoSox (0.5 mM, 15 min incubation). The pictures are optical fields under
each condition as imaged by laser scanning confocal microscopy and are representative of two independent experiments yielding similar outcomes.
White bar: 50 mm. The insets show selected enlargements rendered to highlight the intracellular compartmentalization of the fluorescent signal. (C)
Histogram showing the quantitative analysis of the intracellular fluorescent signal along with the statistical significance of the differences; bars
indicate mean values 6 SD from 5 randomly selected optical fields/experiment taken under each condition (each optical field contained <20 cells).
See under Materials and Methods for further details.
doi:10.1371/journal.pone.0090917.g006
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an antioxidant mechanism. This latter might be accomplished
either directly by ROS-scavenging chemical properties or
indirectly providing antioxidant metabolites.
Discussion
Although the mechanism of organ failure and dysfunction after
HS and re-perfusion has not been completely elucidated,
inadequate tissue perfusion leads to gross metabolic disturbance,
mitochondria dysfunction/energy failure, severe acidosis, and the
generation of ROS, leading to consumption of endogenous
antioxidants [22,23]. However, rapid replacement with large-
volume resuscitation through the use of intravenous fluids and
blood products [4] has been shown to increase hemorrhage
volume and decrease survival compared with either low-volume or
delayed fluid replacement [24]. Therefore, the potential for
resuscitating injured patients with HS without the need for blood
and blood product remains quite attractive [25].
In the present study, we tested the in vivo pro-survival effects of
pHPP in a rat model of profound HS. The protocol was designed
to closely mimic the preclinical management of poly-trauma
patients. The results shown in Fig. 2 show that survival time was
significantly prolonged when hemorrhaged rats were treated with
a small volume of pHPP solution in the absence of major
sanguinous or asanguinous resuscitation. In a previous study,
Macias et al. [26] showed that hemorrhaged rats treated with
0.5 mmol/kg of EP dissolved in 2.8 mL/kg of saline survived
significantly longer compared with rats treated with the same
volume of vehicle alone. Herein, we showed that an even smaller
molar dose of pHPP (0.25 mmol/kg) in the same volume of saline
(2.8 mL/kg) conferred a survival advantage, and the prolongation
of survival was greater than the one previously reported by Macias
and colleagues in their study of EP solution. Remarkably, we
found that the same amount of pHPP given in 2% EBV of saline
resulted in approximately 50% survival at 4 h after rats were
subjected to more than 50% blood loss. To note, the estimated
concentrations of pHPP in the residual blood volume after
hemorrhage were 6.7 mM and 7 mM following the 4% and 2% of
the EBV perfusion, respectively. Furthermore, it is important to
note that treatment with pHPP solution prolonged survival
without causing a substantial increase in blood pressure. Thus,
treatment with pHPP could be used to ‘‘buy time’’ until definitive
control of surgical bleeding without promoting excessive further
blood loss [27].
Notably, there was no statistically significant difference between
HGA (in 2% EBV) and pHPP (either in 4% or 2% of EBV). This
finding supports the notion that metabolism of pHPP via the phe/
tyr catabolic pathway is important for its therapeutic effect.
Consistently, when DCA was co-administered with pHPP or
infused alone, only 1 of 6 animals in each group survived until 4 h.
Cellular ATP levels are depleted in rats (and, presumably,
humans) with shock due to hemorrhage [28]. Interestingly, no
significant benefit with regard to tissue bioenergetics was observed
following resuscitation with ethyl pyruvate-supplemented Ringer’s
solution in a swine model of HS [29]. Although we did not
measure cellular ATP levels in the rat HS experiments reported
here, we clearly demonstrated that pHPP effectively supports
mitochondrial respiration in cultured EA.hy 926 cells. The
relatively high rate of pHPP oxidative degradation is likely due
to the fact that pHPP bypasses tyrosine transaminase and the
phenylalanine hydroxylase steps in the phe/tyr catabolic pathway;
both of these enzymatic reactions are tightly regulated and limit
the rate of catabolism of these amino acids [30,31].
The end-products of pHPP catabolism in the cytoplasm are
fumarate and acetoacetate. Both of these compounds can enter
into mitochondria and support the tricarboxylic acid cycle either
as intermediates or substrates (see scheme in Fig. 1 and
experimental evidences provided in Fig. 5). Importantly, the
enhanced delivery of reducing equivalents to the mitochondrial
respiratory chain is fully coupled to the synthesis of ATP as shown
by both the enhanced oligomycin-sensitive OCR and RCR (Fig. 4).
Consequently, pHPP appears to be an efficient bio-energizer
providing extra ATP to support adaptation to stressing conditions
(over a time scale of a few minutes) or to foster normal cell growth
(over a time scale measured in days) as shown in Fig. 3. This
property would result beneficial to cells/tissues experiencing a
shortage of metabolic substrates, serum factors or oxygenation as
that attained following a severe HS. Most notably, the in vitro-
tested concentrations of pHPP were in the same millimolar range
used in the in vivo model of HS. This suggests that, at least in part,
the therapeutical efficacy of pHPP can be traced back to its
metabolic activity.
A further property that we tested and proved for pHPP was its
antioxidant activity (Fig. 6). The enone moiety present in the
molecule is likely to provide the chemical basis for its ROS
scavenging action as proposed for EP and pyruvate sharing a
similar feature [18]. It is worth noting that since the ROS-probe
used detects intramitochondrial ROS this implies that pHPP (or
related metabolites) exerts its antioxidant action within the
mitochondrial compartment. Whatever is the precise mechanism,
which warrants further investigation, the antioxidant activity of
pHPP may contribute to counter-act the cytotoxic effect of a pro-
oxidant conditions like that establishing under hemorrhagic shock.
Other possible activities of pHPP (anti-inflammatory in particular)
are currently under scrutiny.
In conclusion, the data presented support the view that pHPP
might be useful for the management of traumatically injured
patients in order to prolong their period of survival time after
losing large quantities of blood. Additional pre-clinical studies with
this compound appear to be warranted.
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